9.33 USD
▲+0.10+10.81%
盘后 8.22 -2.35%
2026-08-03
市值
$664.20M
市盈率
—
EPS
-0.89
股息率
—
52 周区间
1.94 – 12.14
成交量
1.87M
Beta
0.09
目标价
19.91
52W 低 1.9452W 高 12.14
价格走势
公司简介
Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in the development of chimeric antigen receptor cell therapy in light chain Amyloidosis and immune-mediated diseases in the United States and Australia. The company’ lead product is NXC-201 for relapsed/refractory AL Amyloidos. Immix Biopharma, Inc., was incorporated in 2012 and is headquartered in Los Angeles, California.